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Abstract
Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease 
progression by about 50% in estrogen receptor-positive breast cancer patients, but late 
relapse can still occur after anti-estrogens have been discontinued. In these patients, 
excessive androgen production may account for renewed excessive estrogen formation 
and increased risks of late relapse. In the 50% of patients who do not benefit with 
anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to 
treatment. Androgen receptor and epidermal growth factor receptor overexpression are 
recognized mechanisms of endocrine resistance suggesting the involvement of androgens 
as activators of the androgen receptor pathway and as stimulators of epidermal 
growth factor synthesis and function. Data from a series of prospective studies on 
operable breast cancer patients, showing high serum testosterone levels are associated 
to increased risk of recurrence, provide further support to a role for androgens in 
breast cancer progression. According to the above reported evidence, we proposed to 
counteract excessive androgen production in the adjuvant setting of estrogen receptor-
positive patients and suggested selecting postmenopausal patients with elevated levels 
of serum testosterone, marker of ovarian hyperandrogenemia, for adjuvant treatment 
with a gonadotropins-releasing hormone analogue (medical oophorectomy) in addition 
to standard therapy with anti-estrogens. The proposed approach provides an attempt of 
personalized medicine that needs to be further investigated in clinical trials.
Introduction
Breast cancer patients with early-stage estrogen receptor 
(ER)-positive tumors are commonly treated with anti-
estrogens, tamoxifen and aromatase inhibitors, to 
prevent cancer recurrence. Five years of adjuvant therapy 
significantly improve the outcomes of these patients 
compared to none therapy (Smith et  al. 2014, Sestak 
& Cuzick 2015, Sestak et  al. 2016), but, despite their 
effectiveness, adjuvant hormonal treatments encounter 
two major clinical problems: high rate of de novo or 
acquired resistance to anti-estrogens, that prevents about 
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50% of patients to benefit with the therapy (Rechoum 
et  al. 2014, Fuji et  al. 2014, Ciupek et al. 2015) and 
occurrence of late relapse after anti-estrogens have been 
discontinued (Smith et  al. 2014, Sestak & Cuzick 2015, 
Sestak et al. 2016).
Available evidence suggests that high levels of serum 
testosterone are risk factors for progression of breast cancer 
(Secreto & Zumoff 1983, Berrino et al. 2005, Micheli et al. 
2007, Emond et al. 2011, Secreto 2012a, Secreto & Zumoff 
2012) and that they may be involved in the occurrence 
of late relapse (Micheli et al. 2007). Furthermore, they are 
implicated in the development of endocrine resistance 
by stimulation of androgen receptor (AR) and epidermal 
growth-factor receptor (EGFR) overexpression (Fuji et al. 
2014, Rechoum et al. 2014, Ciupek et al. 2015).
In a recently published article (Secreto et  al. 2016), 
we proposed a novel approach to prevent breast cancer 
by administering a gonadotropins-releasing hormone 
(GnRH) analogue to healthy postmenopausal women 
with high levels of testosterone, marker of ovarian 
hyperandrogenemia. Similarly, in this paper, we proposed 
(i) to select ER-positive postmenopausal breast cancer 
patients based on high levels of serum testosterone 
and (ii) to inhibit excessive testosterone production 
by administration of a GnRH analogue (medical 
oophorectomy) in addition to standard adjuvant therapy 
with anti-estrogens.
In the next section, we have discussed the role of 
androgen excess in breast cancer development, the 
association of high testosterone levels with risk of disease 
progression, the role of androgen excess in late relapse and in 
resistance to endocrine therapy, the postmenopausal ovary 
as source of excessive testosterone production, subsequently 
we have proposed the statement of our proposal.
Discussion
Role of androgen excess in breast cancer development
The androgen excess theory, developed in studies by 
our and other groups over the last 45  years, states that 
high circulating levels of androgens represent a marker 
of increased risk of breast cancer in healthy women 
and of increased risk of relapse in women with breast 
cancer (Secreto 2012b). The mammary gland acts as an 
important para-endocrine organ capable of synthesizing 
active steroids from inactive or less active precursors 
holding the enzymatic supply for converting either one 
steroid into another of the same family (e.g. testosterone 
to dihydrotestosterone, estrone to estradiol) or one into a 
different family (testosterone to estradiol, androstenedione 
to estrone). A simplified scheme of the biosynthetic 
pathway of sex steroids and the related enzymes are 
reported in both Fig. 1 and in Table 1, respectively.
In ER-positive tumors, androgen excess operates 
through the increasing conversion into estrogens which 
are the final stimulators of cancer growth. The finding 
of a significant relationship of blood testosterone levels, 
Figure 1
Biosynthetic pathway of sex steroids. The 
androgen to estrogen conversion is shown in bold 
to emphasize that estrone and estradiol can only 
derive from androstenedione and testosterone, 
respectively. DHT originates from testosterone 
and cannot be transformed into estrogens. 
DHT = dihydrotestosterone. Reproduced, with 
permission, from Secreto (2012a).
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but not of estradiol levels, with the ER content of tumors 
(Secreto et al. 2009, 2011) supports this mechanism. The 
observation that testosterone stimulates development 
of ER-positive tumors has been previously described in 
two publications by our group (Secreto 2012a, Secreto 
et al. 2016). In brief, inside the cancer cell, testosterone 
is converted into its two biologically active metabolites: 
(i) estradiol, which stimulates proliferation of breast 
epithelium by binding to ER, and (ii) dihydrotestosterone 
(DHT), which counteracts the proliferative effect of 
estradiol by binding to AR. In hormone-dependent 
tumors, the equilibrium between the pro-proliferative 
effect of estradiol and the anti-proliferative effect of 
DHT is still maintained, although at a higher level than 
in normal cells. Thus, in this condition, cancer growth 
remains under hormonal control for some time; however, 
the proliferative effect of estrogens ultimately prevails 
if the source of excessive androgen production is not 
removed (Fig. 2).
In addition to increased conversion into estrogens, 
androgen excess can stimulate breast cancer growth by 
both a direct bind to AR (Farmer et al. 2005, Doane et al. 
2006) and an increase in the epidermal growth factor 
(EGF) production, a known stimulator of breast epithelial 
cells proliferation (Lippman et al. 1986, Borellini & Oka 
1989), whose synthesis and function are under the control 
of androgens (Labows et al. 1979, Pascall 1997) (Table 2). 
EGF is synthesized in specialized apocrine glands (Labows 
et al. 1979, Pascall 1997) and in the apocrine epithelium 
of the human mammary gland (Collette et  al. 1986, 
Boccardo et al. 2001, Parish et al. 2007). Apocrine cysts are 
commonly found in the human breast and large areas of 
apocrine metaplasia are frequently present in the breast 
of women with mammary cancer (Mazoujian et al. 1983, 
Dixon et  al. 1985, Wellings & Alpers 1987), suggesting 
increased local production of EGF.
High testosterone levels and risk of disease progression: 
epidemiological evidence
A number of epidemiological prospective studies carried 
out in postmenopausal healthy women consistently 
reported the association of both elevated levels 
Table 1 Enzymes involved in sex steroid production. Reproduced, with permission, from Secreto (2012a).
Enzyme Activity
Aromatase Irreversible aromatization of:
 Androstenedione to estrone 
 Testosterone to estradiol
17β-HSD* family  
17β-HSD5 17β-reduction of androstenedione to testosterone
17β-HSD1 17β-reduction of estrone to estradiol
17β-HSD2 17β-oxidation of:
 Testosterone to androstenedione
 Estradiol to estrone
Sulfatase Conversion of estrone sulfate to estrone
Sulfotransferase Conversion of estrone to estrone sulfate
5α-reductase 5α-reduction of testosterone to dihydrotestosterone
*17β-hydroxysteroid dehydrogenase.
TESTOSTERONE
conversion to
.
ESTRADIOL DHT
pro-proliferative anti-proliferative
.
Androgen/Estrogen
Equilibrium
Control of Cell Proferation
Figure 2
Central role of testosterone in breast epithelial cells proliferation. 
Simplified scheme to describe the control of breast epithelial cells 
proliferation by testosterone through conversion into its two biological 
active metabolites: estradiol and dihydrotestosterone (DHT). The 
equilibrium between the pro-proliferative effect of estradiol and the 
anti-proliferative effect of DHT allows proper control of breast 
epithelium proliferation during a woman’s life. In presence of androgen 
excess, the proliferative effect of estrogens will ultimately prevail if the 
source of excessive androgen production is not removed.
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of androgens and estrogens with increased risk of 
ER-positive breast cancer (Key et  al. 2002). In contrast, 
a limited number of observational studies evaluated the 
association of androgen levels with risk of recurrence 
in women with breast cancer. In a series of prospective 
studies (Berrino et al. 2005, Micheli et al. 2007, Secreto 
2012a, Secreto & Zumoff 2012), we found that the 
frequency of disease progression was greater in patients 
with baseline high serum testosterone levels (higher than 
0.40 ng/mL, the median value of the group) than that in 
patients with low levels (below the median value). In one 
of these studies (Berrino et  al. 2005), the use of diet to 
lower the circulating testosterone reduced the frequency 
of disease progression, suggesting that correction of 
hyperandrogenemia improved the outcomes of these 
patients. In a different observational study (Micheli 
et al. 2007) the authors have detected a better outcome 
for the low testosterone group than that for the high 
testosterone group, which became evident after the third 
year of follow-up. Furthermore, they have observed a 
constant and progressive increase in cancer survival in 
breast cancer patients at low testosterone serum levels 
during the 15-year follow-up period. Interestingly, in 
this low serum testosterone level group, the event-free 
survival at 10 years was 70% of the baseline group, which 
was only modestly declined at 15 years to 67%. On the 
contrary, event-free survival in the high testosterone 
group was already lower than that in the previous 
group at 10  years of follow-up, with only 52% event-
free survival, reaching a very low 36% at 15  years of 
follow-up. The finding showed that after 10  years of 
follow-up virtually no further recurrence appeared in the 
low testosterone group whereas new events continued 
to emerge in the high testosterone group, suggesting 
that high testosterone levels at baseline may be regarded 
as a marker and player of late relapse. Confirmatory 
evidence that a high testosterone level is a factor of risk 
of breast cancer progression has been obtained in the 
largest of our prospective studies on 361 ER-positive 
postmenopausal patients. After 5.6  years of follow-up, 
we found that the rate of recurrence was almost double 
in the high testosterone group (14.7%) than that in the 
low testosterone group (7.9%) (P = 0.037) (Secreto 2012a, 
Secreto & Zumoff 2012). Data from a study by Emond 
et al. (2011) reported higher risk of cancer recurrence in 
patients with elevated levels of testosterone than that 
with normal levels. These study results are consistent 
with our findings. In contrast, Rock et al. (2008) found 
that increased risk of relapse was only associated with 
elevated levels of estradiol.
In contrast to increased risk of relapse observed in 
early breast cancer, excessive androgen production 
appeared to be a marker of favorable response to 
ovariectomy in metastatic disease (Secreto & Zumoff 
1983). An explanation of this paradoxical effect is that 
androgen excess stimulates cancer progression and 
that ovariectomy achieves remission of metastases by 
removing the source of excessive androgen production. 
If ovariectomy improves the remission-rate of metastases 
by lowering androgen levels in patients with advanced 
disease then suppression of excessive ovarian androgen 
production in early disease should decrease the risk 
of future recurrence. Our reasoning is supported by 
the evidence produced by our team that remission of 
metastases after oophorectomy was more frequent and 
of longer duration in patients with high levels of urinary 
androgen than that with normal levels independently 
from the menopausal status (Grattarola 1976, Secreto et al. 
1984). We have also observed that short-term cycles and 
low doses of dexamethasone were efficacious to inhibit 
adrenal androgen production when androgen levels 
started to rise again after ovariectomy. The combined 
treatment ovariectomy + dexamethasone obtained the 
best outcome (Table 3).
Androgen excess as a factor of risk of late relapse and of 
resistance to anti-estrogens
In the adjuvant therapy of ER-positive tumors, 5 years of 
treatment with anti-estrogens reduces the incidence of 
disease progression by about 50%, however, the disease 
progression can still occur after the therapy has been 
Table 2 Principal mechanisms by which androgen excess can stimulate growth of different breast cancer sub-types.
Androgen excess
Tumor type Mechanisms of growth stimulation
ER-positive (often also AR-positive) Increased conversion of testosterone to estradiol
ER-negative/AR-positive Direct binding of testosterone and DHT* to AR
ER-negative/AR-negative Increased synthesis of epidermal growth factor†
*DHT, dihydrotestosterone; †this mechanism is active in several tumors type.
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discontinued (Smith et al. 2014, Sestak & Cuzick 2015, Goss 
et al. 2016). Extending adjuvant treatments for additional 
5 years efficiently reduces the incidence of late relapse but 
is associated with increased risk of adverse side effects of 
anti-estrogens (Davies et al. 2013, Goss et al. 2016, Sestak 
et  al. 2016). Ten years of adjuvant treatments should be 
proposed only to patients at increased risk of late relapse, 
who will probably benefit with it, and should be avoided to 
the majority of patients for whom extended therapy will be 
useless and potentially dangerous (Smith et al. 2014, Sestak 
& Cuzick 2015). Clinical and pathological parameters are 
commonly used as predictors of late recurrence. Multi-
gene signatures might also be used to identify women at 
increased risk of late relapse but, actually, these biomarkers 
are not routinely adopted in the clinical practice (Smith et 
al. 2014, Sestak & Cuzick 2015). Thus, we have suggested 
that high testosterone levels might be regarded as an 
additional prognostic marker.
According to the mechanism proposed above on the 
role of androgen excess in stimulating ER-positive tumors, 
anti-estrogens are effective against the consequence 
of androgen excess, i.e. increased estrogen synthesis 
and activity. However, they are ineffective against the 
source of androgen excess itself, which persists during 
adjuvant treatments supporting both the constant 
estrogen formation and the risk of late relapse at therapy 
discontinuation.
The prolonged beneficial carryover effect observed 
after suspension of anti-estrogens (Davies et al. 2013, 
Smith et al. 2014, Sestak & Cuzick 2015) suggests that 
stimulation of cancer cells by renewed estrogen formation 
can require a long-time interval before inducing cancer 
progression. The conception of testosterone as predictor 
of breast cancer relapse is corroborated by the findings by 
Micheli et al. (2007) that after 10 years since diagnosis of 
disease progression continued to occur almost exclusively 
in patients with high testosterone levels.
In the 50% of ER-positive patients who do not benefit 
with anti-estrogen therapy, the effectiveness of therapy 
is limited by de novo or acquired resistance to treatment 
partially due to the AR and EGFR biological action. AR and 
EGFR overexpression are well documented mechanisms of 
anti-estrogens resistance (Massarweh et al. 2008, DeAmicis 
et al. 2010, Osborne & Schiff 2011, Rechoum et al. 2014, 
Fuji et al. 2014, Ciupek et al. 2015), which suggest the 
involvement of androgens both as activators of the AR 
pathway and as stimulators of EGF synthesis and function. 
Discussing multiple mechanisms of endocrine resistance 
in detail (DeAmicis et al. 2010, Rechoum et  al. 2014) is 
beyond the scope of our paper: we only wish to emphasize 
the role of androgens in this process and the need of 
inhibiting excessive androgen production in addition to 
administration of anti-estrogens.
The postmenopausal ovary as source of excessive 
testosterone production
In postmenopausal women, estrogen formation 
occurs in peripheral tissues by aromatization of 
adrenal androgen precursors (dehydroepiandrosterone 
(DHEA), dehydroepiandrosterone-sulfate (DHEAS), 
androstenedione) and ovarian androgen precursors 
(testosterone, androstenedione) (Burger 2002). The 
ovary is an important source of testosterone and other 
androgens in postmenopausal women (Fogle et al. 
2007). Synthesis takes place in the stromal tissue under 
the stimulus of the gonadotropin luteinizing hormone 
(LH) (Adashi 1994, Laughlin et al. 2000). Continuous 
stimulation by high LH levels can lead to stromal cell 
hyperplasia and hence increased levels of circulating 
testosterone (Adashi 1994, Lucisano et al. 1986, Sluijmer 
et al. 1998, Jongen et al. 2003). Ovarian stromal 
hyperplasia is a characteristic feature of breast cancer 
patients, recognized over 60  years ago by Sommers & 
Teloh (1952) in 80% of women who had died of breast 
cancer and subsequently confirmed in studies by our 
group that have documented high testosterone levels 
in patients with breast cancer and ovarian interstitial 
cell hyperplasia (Grattarola 1973, 1976, Secreto & 
Zumoff 1983, Grattarola et al. 1974). Extensive evidence 
suggests that high serum testosterone levels are a marker 
of ovarian hyperandrogenemia (Lucisano et al. 1986, 
Table 3 Incidence of objective remission after oophorectomy 
alone or in combination with dexamethasone (DXM) in 
metastatic breast cancer patients, according to normal or 
above normal urinary androgen (testosterone and/or 
androstanediol) excretion values. Adapted, with permission, 
from Secreto et al. (1984). Reviews on Endocrine-Related 
Cancer 14 (Supplement) p55.
 
Number of 
patients 
Remission
Patients and treatment N* %
Normal androgen excretors 61 (8)* 16 (2) 26.2
Oophorectomy alone    
High androgen excretors 46 (6) 25 (3) 54.3
Oophorectomy alone    
High androgen excretors 26 (3) 24 (3) 92.3
Oophorectomy + DXM    
*Number of postmenopausal patients in parenthesis.
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Adashi 1994, Sluijmer et al. 1998, Laughlin et al. 2000, 
Burger 2002, Jongen et al. 2003, Fogle et al. 2007) which 
can be corrected by oophorectomy (Adashi 1994, Sluijmer 
et al. 1998, Laughlin et al. 2000, Jongen et al. 2003, Fogle 
et al. 2007, Kotsopoulos et al. 2012). In a study of BRCA1 
and BRCA2 mutation carriers, Kotsopoulos et al. (2012) 
observed a significant decrease in the risk of breast cancer 
in women who are oophorectomized after menopause 
than that in women in natural menopause and suggested 
that the reduction of circulating testosterone levels after 
oophorectomy might account for its protective effect.
Statement of our proposal
In consideration of the data included in this report, we 
believe that there is enough evidence to support the 
development of a randomized clinical trial to test the 
hypothesis of whether the addition of GnRH analogues 
to anti-estrogens improves outcomes of postmenopausal 
patients with high testosterone levels. In these women 
treated with GnRH analogues, circulating testosterone 
should be regularly checked and the treatment interrupted 
when testosterone values decrease well under the cut-off 
value that separates elevated from normal levels (it may 
vary from population to population, from laboratory to 
laboratory, from analytical method to analytical method). 
Treatment should be then resumed when testosterone 
levels rise again after the initial decrease. The evaluation 
of serum testosterone levels should continue at regular 
time intervals for several years after that therapy with anti-
estrogens has been discontinued and GnRH analogues 
should be administered when necessary, i.e. whenever 
testosterone levels rise again.
A limitation of our proposal is that the method for 
testosterone measurement is not standardized and actually 
there is not a general agreement about the normal values 
of testosterone in the general population. The choice of 
the cut-off value which more efficiently separates high 
from normal levels is an important issue and must take 
several variables into account and should be tested on 
a clinical trial. Actually, liquid chromatography-tandem 
mass spectrometry (LC–MS/MS) is the preferred method 
for measurement of low testosterone concentrations in 
women (Ketha et  al. 2014). The LC–MS/MS technique 
permits simultaneous quantification of several steroids 
in a single run thereby allowing the organization of a 
supplementary hormonal study aimed to improve the 
knowledge on the role of sex steroids in breast cancer 
recurrence and resistance to anti-estrogens.
Tolerability and side effects of GnRH analogues in 
postmenopausal women have been discussed in our 
recently published paper on breast cancer prevention 
(Secreto et al. 2016). Here, we synthetically report that 
GnRH analogues are well tolerated and are not associated 
to significant side effects, especially no hot flushes, 
according to the few studies that examined the effect 
of medical oophorectomy at this age (Crighton et  al. 
1989, Hughes et  al. 1991). In particular, inhibition of 
the synthesis of the gonadotropin follicle-stimulating 
hormone (FSH) does not influence the synthesis of 
estrogens in the adipose tissue (Folkerd et al. 1982, Bulun 
et al. 2005), which is the source of estrogen production 
at postmenopausal age. In a study of adjuvant therapy in 
premenopausal breast cancer patients, Pagani et al. (2014) 
found that ‘the adverse-event profiles of exemestane 
plus ovarian suppression and tamoxifen plus ovarian 
suppression were similar to those seen in postmenopausal 
women’. Overall, co-administration of GnRH analogues 
should not worsen the adverse effects of anti-estrogens, 
in particular should not increase the risk of bone-related 
toxic effects associated to aromatase inhibitors, but the 
scanty information available on medical oophorectomy 
side effects in postmenopausal women require close 
follow-up of the treatment.
Conclusion
The aim of this report is to propose to administer GnRH 
analogues in addition to anti-estrogens to ER-positive 
postmenopausal patients with high testosterone levels 
to increase both disease-free survival and total survival 
in these patients. The scope of this article is to open 
innovative avenues for breast cancer clinical research in 
the rather unexplored field of the role of androgens in 
breast cancer development.
Suppression of estrogen synthesis and activity is the 
objective of adjuvant anti-estrogen hormonal therapy. We 
consider that such an approach is incomplete in patients 
with high testosterone levels and we propose to complete 
the treatment through the correction of the basic 
endocrine abnormality responsible of excessive androgen 
production. After the discontinuation of anti-estrogens, 
renewed estrogen synthesis is fast and abundant in patients 
with a severe degree of ovarian stromal hyperplasia, 
leading to disease progression in a short time. In patients 
with a mild degree of ovarian stromal hyperplasia, estrogen 
synthesis will be slower and cancer relapse will require 
a longer time, explaining the observed anti-estrogen 
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beneficial carryover effect (Fig. 3). Administering a GnRH 
analogue inhibits excessive ovarian androgen production 
and preserves from excessive estrogen synthesis restoring 
the normal androgen/estrogen equilibrium.
This innovative therapeuthical approach does not 
completely neutralize the biologically important estrogen 
activity but proposes to restore the normal equilibrium 
between the proliferative effect of estradiol and the anti-
proliferative effect of DHT in patients with high testosterone 
levels. This proposal is based on the administration of 
GnRH analogues in addition to anti-estrogens during the 
5 years of standard adjuvant therapy to revert to normal 
ovarian androgen production. When anti-estrogens are 
suspended, a normal synthesis of estrogens will take 
place from a normal amount of androgen precursors, the 
stimulation of breast epithelial cells will not be unbalanced, 
and occurrence of late relapse will be prevented. In other 
words, normalization of estrogen production may achieve 
the same beneficial effects obtained by extending treatment 
with anti-estrogens but without their dangerous side 
effects. Preservation of the androgen/estrogen equilibrium 
can be monitored by measurement of testosterone levels 
at regular time intervals and can be corrected at any 
time by administration of GnRH analogues whenever 
it is necessary. In conclusion, we expect that lowering 
high testosterone levels and maintaining them low will 
counter endocrine resistance and will reduce the risk 
of early and late relapse, thus improving the outcomes 
obtained by anti-estrogens alone. As a final consideration, 
we emphasize that the proposed approach may provide 
a further step toward personalized therapy, which is the 
objective of modern oncology.
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